


CLAIMS:

1. Compound of Formula I



(I)

wherein

R₁ is substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₄₋₇ alkylcycloalkyl,

wherein the cycloalkyl in R₁ if substituted also in alkylcycloalkyl is substituted with substituents selected from -R_{4'''}, halogen, -SR_{4'''}, -CN, haloalkyl, -NR_{4'''}R_{4'''},

wherein the alkyl, alkenyl and alkynyl in R₁ if substituted are substituted with substituents selected from halogen, -CN, haloalkyl;

R₂ is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl,

wherein the aryl or heterocyclyl in R₂ if substituted is substituted with substituents selected from -R₄, -OR₄, halogen, =O, -OCH₂CH₂OH, -SR₄, -S(O)R₄, -S(O)₂R₄, -CN, haloalkyl, -haloalkoxy, -NR₄R_{4'''}, -NO₂, -NR₄C(O)R_{4'}, -NR₄SO₂R_{4'}, -C(O)OR₄, -C(O)NR₄R_{4'}, -NR₄C(O)NR_{4'}R_{4''}, -S(O)₂NR₄R_{4'}, -NR₄S(O)₂NR_{4'}R_{4''};

R₃ is substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₄₋₇ alkylcycloalkyl, substituted or unsubstituted C₄₋₇ alkylaryl, ~~substituted or unsubstituted C₃₋₆ aryl, substituted or unsubstituted C₃₋₆ heterocyclyl or~~ substituted or unsubstituted C₄₋₇ alkylheterocyclyl,

wherein ~~in R₃ the aryl in alkylaryl, the heterocyclyl in alkylheterocyclyl, the cycloalkyl in alkylcycloalkyl or the cycloalkyl in R₃ if substituted also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl~~ is substituted with substituents selected from -R₄, -OR₄, halogen, =O, -OCH₂CH₂OH, -SR₄, -S(O)R₄, -S(O)₂R₄, -CN, haloalkyl, -haloalkoxy, -NR₄R_{4'''}, -NO₂, -NR₄C(O)R_{4'}, -NR₄S(O)₂R_{4'}, -C(O)OR₄, -C(O)NR₄R_{4'}, -NR₄C(O)NR_{4'}R_{4''}, -S(O)₂NR₄R_{4'}, -NR₄S(O)₂NR₄R_{4''}

and wherein the alkyl, alkenyl and alkynyl as defined in R₃ if substituted are substituted with substituents selected from -OR₄, halogen, -CN, haloalkyl,

R_{3'} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl or unsubstituted C₂₋₆ alkynyl,

alternatively R₃ and R_{3'} taken together with the connecting C-atom may form an substituted or unsubstituted C₃₋₆ cycloalkyl;

wherein the cycloalkyl in R₃ and R_{3'} taken together if substituted is substituted with substituents selected from -R₄, -OR₄, halogen, =O, -OCH₂CH₂OH, -SR₄, -S(O)R₄, -S(O)₂R₄, -CN, haloalkyl, -haloalkoxy, -NR₄R_{4'''}, -NO₂, -NR₄C(O)R_{4'}, -NR₄S(O)₂R_{4'}, -C(O)OR₄, -C(O)NR₄R_{4'}, -NR₄C(O)NR_{4'}R_{4''}, -S(O)₂NR₄R_{4'}, -NR₄S(O)₂NR₄R_{4''}

R₄, R_{4'} and R_{4''} are independently selected from hydrogen or substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl or substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl;

wherein the cycloalkyl in R₄, R_{4'} or R_{4''} if substituted is substituted with substituents selected from -R_{4'''}, halogen, -SR_{4'''}, -CN, haloalkyl, or -NR_{4'''}R_{4'''},

wherein the alkyl, alkenyl and alkynyl in R₄, R_{4'} or R_{4''} if substituted are substituted with substituents selected from halogen, -CN, haloalkyl;

R_{4'''} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc;

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

2. Compound of formula (I) according to claim 1 wherein

R₁ is unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted C₃₋₆ cycloalkyl, unsubstituted C₄₋₇ alkylcycloalkyl;

R₂ is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl;

wherein the aryl or heterocyclyl if substituted is substituted with substituents selected from -R₄, -OR₄, halogen, =O, -OCH₂CH₂OH, -SR₄, -S(O)R₄, -S(O)₂R₄, -CN, haloalkyl - haloalkoxy, -NR₄R_{4'''}, -NO₂, -NR₄C(O)R_{4'}, -NR₄S(O)₂R_{4'}, -C(O)OR₄, -C(O)NR₄R_{4'}, -NR₄C(O)NR_{4'}R_{4''}, -S(O)₂NR₄R_{4'}, -NR₄S(O)₂NR_{4'}R_{4''};

R₃ is unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted C₃₋₆ cycloalkyl, unsubstituted C₄₋₇ alkylcycloalkyl, unsubstituted C₄₋₇ alkylaryl, ~~unsubstituted C₃₋₆ aryl, unsubstituted C₃₋₆ heterocyclyl or unsubstituted C₄₋₇ alkylheterocyclyl;~~

R_{3'} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl or unsubstituted C₂₋₆ alkynyl,

alternatively R₃ and R_{3'} taken together with the connecting C-atom may form an unsubstituted C₃₋₆ cycloalkyl;


R₄, R_{4'} and R_{4''} are independently selected from hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl or unsubstituted C₂₋₆ alkynyl, unsubstituted C₃₋₆ cycloalkyl;

R_{4'''} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or -Boc;

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers~~

~~and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

3. Compound according to claims 1 or 2 wherein the compound of formula I is a compound of formula I'



wherein q is 1, 2, 3 or 4,


R₁ and R₂ are as defined in the previous claims for the compound of formula (I);

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

4. Compound according to claim 3 wherein q is 1;

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

5. Compound according to claims 1 or 2 wherein the compound of formula I is a compound of formula I''



(I'')

wherein R_1 , R_2 and R_3 are as defined in the previous claims for the compound of formula (I);

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

6. Compound according to any one of claims 1 to 5 wherein the compound of formula I, wherein

R_1 is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{4-7} alkylcycloalkyl, wherein

the C_{1-6} alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C_{1-6} alkyl is methyl, ethyl, isopropyl,

the C_{2-6} -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C_{2-6} -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne, and

the C_{3-6} cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably the C_{3-6} cycloalkyl is cyclopropyl;

preferably the alkyl is C₁₋₄ alkyl selected from methyl, ethyl, propyl, butyl;

more preferably R₁ is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl or unsubstituted cyclopropyl;

and/or

R₂ is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl, wherein

the monocyclic aryl is substituted or unsubstituted phenyl;

the monocyclic heterocyclyl is a heterocyclic ring system of one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, thiazole, tetrahydropyran, morpholine, furan, triazole, isoxazole, pyrazole, thiophene, pyrrole, pyrazine, oxopyrrolidine, pyrimidine, preferably the heterocyclyl is pyridine or thiazole;

more preferably R₂ is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine or substituted or unsubstituted thiazole;

R₃ is substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₄₋₇ alkylcycloalkyl, substituted or unsubstituted C₄₋₇ alkylaryl, ~~substituted or unsubstituted C₃₋₆ aryl, substituted or unsubstituted C₃₋₆ heterocyclyl or~~ substituted or unsubstituted C₄₋₇ alkylheterocyclyl; wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, ethyl, isopropyl,

the alkenyl is C₂₋₆-alkenyl, like ethylene, propylene, butylene, pentylene or hexylene,

the alkynyl is C₂₋₆-alkynyl like ethyne, propyne, butyne, pentyne or hexyne, preferably propyne;

the aryl in alkylaryl is phenyl,

the heterocyclyl in alkylheterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole, oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline,

the C₃₋₆ cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

preferably the alkyl is C₁₋₄ alkyl selected from methyl, ethyl, propyl, butyl;

more preferably R₃ is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl or -CH₂CH₂OH;

R_{3'} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl or unsubstituted C₂₋₆ alkynyl, wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably, the C₁₋₆ alkyl is methyl or ethyl,

the C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne;

preferably R_{3'} is hydrogen, substituted or unsubstituted methyl or substituted or unsubstituted ethyl, more preferably R_{3'} is hydrogen, unsubstituted methyl or unsubstituted ethyl;

more preferably R_3 is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl or $-\text{CH}_2\text{CH}_2\text{OH}$, while $R_{3'}$ is hydrogen or substituted or unsubstituted methyl or substituted or unsubstituted ethyl;

most preferably R_3 is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted propyne, unsubstituted benzyl or $-\text{CH}_2\text{CH}_2\text{OH}$ while $R_{3'}$ is unsubstituted methyl or unsubstituted ethyl;

even more preferably R_3 is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, unsubstituted benzyl, unsubstituted propyne or $-\text{CH}_2\text{CH}_2\text{OH}$ while $R_{3'}$ is hydrogen;

or R_3 and $R_{3'}$ taken together with the connecting C-atom may form an substituted or unsubstituted C_{3-6} cycloalkyl; wherein

the C_{3-6} cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably the C_{3-6} cycloalkyl is cyclopropyl;

R_4 , $R_{4'}$ and $R_{4''}$ are independently selected from hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl or substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl; wherein

the C_{1-6} alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C_{1-6} alkyl is methyl,

the C_{2-6} -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C_{2-6} -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne,

the C_{3-6} cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

more preferably R_4 , $R_{4'}$ and $R_{4''}$ are hydrogen or substituted or unsubstituted methyl;

R_{4'''} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or –Boc; wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl,

the C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne;

more preferably R_{4'''} is hydrogen or –Boc;

most preferably R₄, R_{4'} and R_{4''} are hydrogen or substituted or unsubstituted methyl while R_{4'''} is hydrogen or –Boc;

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

7. Compound according to any one of claims 1 to 5 being a compound of formula I, wherein

R₁ is unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted C₃₋₆ cycloalkyl, unsubstituted C₄₋₇ alkylcycloalkyl, wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, ethyl, isopropyl,

the C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne,

the C₃₋₆ cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably the C₃₋₆ cycloalkyl is cyclopropyl;

preferably the alkyl is C₁₋₄ alkyl selected from methyl, ethyl, propyl or butyl;

more preferably R₁ is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl or substituted or unsubstituted cyclopropyl; and/or

R₂ is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl, wherein

the aryl is phenyl;

the heterocyclyl is a heterocyclic ring system of one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, thiazole, tetrahydropyrane, morpholine, furan, triazole, isoxazole, pyrazole, thiophene, pyrrole, pyrazine, oxopyrrolidine, pyrimidine, preferably the heterocyclyl is pyridine or thiazole;

more preferably R₂ is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine or substituted or unsubstituted thiazole;

R₃ is unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl, unsubstituted C₃₋₆ cycloalkyl, unsubstituted C₄₋₇ alkylcycloalkyl, unsubstituted C₄₋₇ alkylaryl, unsubstituted C₃₋₆ aryl, unsubstituted C₃₋₆ heterocyclyl or unsubstituted C₄₋₇ alkylheterocyclyl, wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, ethyl, isopropyl,

the C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne;

the aryl in arylalkyl is phenyl;

the heterocyclyl in alkylheterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline,

the C₃₋₆ cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably the C₃₋₆ cycloalkyl is cyclopropyl;

preferably the alkyl is C₁₋₄ alkyl selected from methyl, ethyl, propyl or butyl;

more preferably R₃ is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, or substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl or -CH₂CH₂OH;

R_{3'} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl or unsubstituted C₂₋₆ alkynyl, wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C₁₋₆ alkyl is methyl, ethyl, isopropyl,

the alkenyl is C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne;

more preferably $R_{3'}$ is hydrogen, substituted or unsubstituted methyl or substituted or unsubstituted ethyl;

more preferably R_3 is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl or $-\text{CH}_2\text{CH}_2\text{OH}$, while $R_{3'}$ is hydrogen or substituted or unsubstituted methyl or substituted or unsubstituted ethyl;

more preferably R_3 is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl or $-\text{CH}_2\text{CH}_2\text{OH}$, while $R_{3'}$ is hydrogen;
or

R_3 and $R_{3'}$ taken together with the connecting C-atom form an unsubstituted C_{3-6} cycloalkyl, wherein

the C_{3-6} cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, most preferably is cyclopropyl or cyclopentyl;

R_4 , $R_{4'}$ and $R_{4''}$ are independently selected from hydrogen or unsubstituted C_{1-6} alkyl, unsubstituted C_{2-6} alkenyl or unsubstituted C_{2-6} alkynyl, unsubstituted C_{3-6} cycloalkyl, wherein the C_{1-6} alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably the C_{1-6} alkyl is methyl,

the C_{2-6} -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C_{2-6} -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne,

the C_{3-6} cycloalkyl is preferably selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

more preferably R_4 , $R_{4'}$ and $R_{4''}$ are hydrogen or substituted or unsubstituted methyl;

R_{4'''} is hydrogen or unsubstituted C₁₋₆ alkyl, unsubstituted C₂₋₆ alkenyl, unsubstituted C₂₋₆ alkynyl or –Boc, wherein

the C₁₋₆ alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl,

the C₂₋₆ -alkenyl, is preferably selected from ethylene, propylene, butylene, pentylene or hexylene,

the C₂₋₆ -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne or hexyne;
more preferably R_{4'''} is hydrogen or –Boc

more preferably R₄, R_{4'} and R_{4''} are hydrogen or substituted or unsubstituted methyl while R_{4'''} is hydrogen or –Boc;

~~optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.~~

8. Compound according to any one of claims 1 to 7 wherein the compound is selected from

- 12-ethyl-8-{2-[3-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-{2-[6-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-[2-(3-fluoropyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-{2-[4-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 8-[2-(3-chloropyridin-2-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 8-[2-(6-aminopyridin-2-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-isopropyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-isopropyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one dihydrochloride
- 12-ethyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one


- (R)-2,4-dimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 12-ethyl-8-{2-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-[2-(6-methoxypyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-[2-(6-hydroxypyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzene-1-sulfonamide
- 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N-methylbenzene-1-sulfonamide
- 12-ethyl-8-{2-[3-(trifluoromethoxy)phenyl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- (R)-4-ethyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 12-ethyl-8-(3-nitrophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(3-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- tert-butyl 4-(2-(12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate
- methyl 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzoate
- 12-ethyl-8-[2-(pyridin-4-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-[2-(pyridin-3-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(4-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(2-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzonitrile
- 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N,N-dimethylbenzamide
- 8-[2-fluorophenethyl]-12-methyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 8-[2-fluorophenethyl]-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- (R)-2-isopropyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-ethyl-9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-ethyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(3-fluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-cyclopropyl-9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-isopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2-fluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(3-fluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2-fluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-cyclopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-cyclopropyl-9-(3-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

- (R)-4-ethyl-9-(3-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 8-(3-fluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride
- (R)-2,4-dimethyl-9-(3-(trifluoromethyl)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2,4-dimethyl-9-(2-(trifluoromethoxy)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2-fluorophenethyl)-2-isopropyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(3-fluorophenethyl)-2-isopropyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2,4-dimethyl-9-(2-(trifluoromethyl)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2,6-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2,5-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2,3-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-ethyl-9-(2-fluorophenethyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-ethyl-9-(3-fluorophenethyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 2,2,4-trimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 12-methyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 8-(3-aminophenethyl)-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- N-[3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]acetamide
- [3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]urea
- 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N-methylbenzamide
- 12-ethyl-8-(2-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(3-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(4-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride
- 8-[2-(2-aminothiazol-4-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 2,2-diethyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 4-cyclopropyl-9-(2-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 8-(2,5-difluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 8-(2,3-difluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one

- 10-(2-fluorophenethyl)-14-methyl-6-oxa-10,14-diazadispiro[4.1.5.3]pentadecan-15-one
- 10-(3-fluorophenethyl)-14-methyl-6-oxa-10,14-diazadispiro[4.1.5.3]pentadecan-15-one
- (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 8-(2,5-difluorophenethyl)-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(3-fluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- 12-ethyl-8-(2-fluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
- (R)-9-(2,3-difluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2,4-diethyl-9-(2-fluorophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2,4-diethyl-9-(3-fluorophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-ethyl-9-(3-fluorophenethyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 4-ethyl-9-(3-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 4-ethyl-9-(2-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-ethyl-9-(2-fluorophenethyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2,5-difluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(3-fluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(2-fluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(2,3-difluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 4-cyclopropyl-9-(2,3-difluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 4-cyclopropyl-9-(2,5-difluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-9-(2,3-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(2,5-difluorophenethyl)-4-ethyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(2,3-difluorophenethyl)-4-ethyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- 9-(2,5-difluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-cyclopropyl-9-(2,3-difluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-cyclopropyl-9-(2,5-difluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-4-methyl-9-phenethyl-2-(prop-2-yn-1-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
- (R)-2-(2-hydroxyethyl)-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, or
- (R)-2-benzyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

9. Process for the preparation of a compound of general formula (I)




(I)

wherein

R_1 , R_2 , R_3 and R_3' are as defined in the preceding claims;


which comprises the steps of

(a) reacting a compound of formula V



(V)


with a compound of formula VI



(VI)

wherein W and LG are leaving groups, R_3 and R_3' are as defined in the preceding claims ;

to obtain a compound of formula VII




(VII)

and

- (b) Carrying out a cyclisation of the resulting compound in a suitable solvent, in the presence of a strong base and at a temperature comprised between -78°C and the reflux temperature.

10. Process for the preparation of a compound of general formula (I')




(I')

wherein q is 1, 2, 3 or 4 and R₁ and R₂ are as defined in the preceding claims;


which comprises the steps of

(a) reacting a compound of formula V



(V)


with a compound of formula XX



(XX)

wherein W and LG are leaving groups, q is as defined in the preceding claims;


to obtain a compound of formula XXI



(XXI)

wherein W and LG are leaving groups, q is as defined in the preceding claims;

(b) carrying out a cyclisation of the resulting compound in a suitable solvent, in the presence of a strong base and at a temperature comprised between -78°C and the reflux temperature ; leading to a compound of formula XXII,



(XXII)

(c) and treating with a strong base such as lithium diisopropylamide or potassium tert-butoxide, in an aprotic solvent such as tetrahydrofuran, at a suitable temperature, preferably cooling.

11. A pharmaceutical composition which comprises a compound as defined in any of claims 1 to 8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
12. A compound as defined in any of claims 1 to 8 for use as a medicament.
13. A compound as defined in any of claims 1 to 8 for use as a medicament for the treatment of pain, especially medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.